Keyword: Exondys 51

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

Sarepta Therapeutics’ DMD therapy Exondys has already been knocked for its skimpy clinical data. Now a price watchdog says it’s also too expensive.

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.

Sarepta’s new CEO pick, Doug Ingram, wins plaudits for commercial savvy, CNS expertise—and sets the stage for more M&A chatter.

Should drugs that win conditional FDA approval command the same high prices as products that undergo the full menu of agency scrutiny?

PTC says it'll charge $35,000 for Emflaza, the Duchenne drug it bought from Marathon in March, amid a brouhaha over its $89,000 list price. Is the new sticker low enough?

You know that old saw about every med school graduate winning the “Doctor” title? Something similar could apply to Sarepta’s newly approved Duchenne muscular dystrophy med Exondys 51.